免疫系统
肝损伤
医学
免疫学
病理
生物信息学
炎症
生物
癌症研究
缺血性损伤
抗体
胃肠系统
作者
Irene Díaz Alberola,Daniel Enrique Di Zeo-Sánchez,Vanesa Garrido‐Rodríguez,Carlos Lopez Gomez,Cristina Rodriguez‐Diaz,Raúl J Andrade,M. Isabel Lucena,Marina Villanueva Paz,Eduardo García‐Fuentes
标识
DOI:10.1016/j.apsb.2026.04.014
摘要
Drug-induced liver injury (DILI) is an adverse hepatic reaction with a complex etiopathogenesis, involving direct cellular damage by the drug, immune-mediated mechanisms, and host and environmental factors. The gut microbiota has recently been recognized as a key player in human physiopathology. In DILI, animal models and patients have shown significant alterations in gut microbiota composition. Evidence indicates that patients with DILI often present intestinal barrier dysfunction, characterized by increased permeability and the translocation of pathogen-associated molecular patterns (PAMPs) to the liver. This process may contribute to the onset or aggravation of liver injury by triggering harmful immune responses. Furthermore, dysbiosis can alter bacterial metabolite production, thereby affecting intestinal and hepatic homeostasis. The gut microbiota can also modify the efficacy and toxicity of drugs on an individual level, thereby increasing the risk of DILI. This review provides an overview of the current evidence on the mechanisms by which the gut microbiota contributes to inflammation, immune recruitment, and exacerbation of liver damage in DILI. A more in-depth understanding of how the gut microbiota alters intestinal and hepatic homeostasis is essential for advancing our knowledge of DILI pathogenesis, integrating novel biomarkers into clinical practice, and developing microbiota-based interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI